Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. Everyday Health independently vets all recommended ...

Amgen announced new Repatha trial results from its landmark Phase 3 VESALIUS-CV study. The data showed Repatha (evolocumab) cut the risk of a first heart attack by 36%. It also reduced the risk of ...

Merck's new pill, enlicitide, and Amgen's longtime Repatha shot are showing heart attack risk-lowering potential, and researchers have made progress on the gene-editing front. The New York Times: New ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac events (MACE) in patients with atherosclerosis or high-risk diabetes, but ...

(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...

Please provide your email address to receive an email when new articles are posted on . Evolocumab is the first PCSK9 inhibitor to demonstrate effectiveness in primary and secondary prevention ...

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. NEW ORLEANS — A pill designed to further lower ...

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...

Methylprednisolone is a generic prescription oral tablet used for certain inflammatory and autoimmune conditions in adults and some children. Dosage of this medication varies depending on the ...

The collaboration with Amgen reduces out-of-pocket costs for patients and expands access to an innovative cholesterol-lowering therapy “In a healthcare system where affordability too often dictates ...